KR20210032437A - 심부전의 치료를 위한 신규한 약제학적 용도 - Google Patents
심부전의 치료를 위한 신규한 약제학적 용도 Download PDFInfo
- Publication number
- KR20210032437A KR20210032437A KR1020217004177A KR20217004177A KR20210032437A KR 20210032437 A KR20210032437 A KR 20210032437A KR 1020217004177 A KR1020217004177 A KR 1020217004177A KR 20217004177 A KR20217004177 A KR 20217004177A KR 20210032437 A KR20210032437 A KR 20210032437A
- Authority
- KR
- South Korea
- Prior art keywords
- valsartan
- sacubitril
- molar ratio
- patient
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 69
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 183
- 229960004699 valsartan Drugs 0.000 claims description 183
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims description 157
- 229960003953 sacubitril Drugs 0.000 claims description 157
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 61
- 230000000977 initiatory effect Effects 0.000 claims description 39
- 238000001990 intravenous administration Methods 0.000 claims description 39
- 238000004448 titration Methods 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 37
- 102400001263 NT-proBNP Human genes 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 30
- 230000035488 systolic blood pressure Effects 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 15
- 230000001154 acute effect Effects 0.000 claims description 15
- 239000002934 diuretic Substances 0.000 claims description 15
- 230000000747 cardiac effect Effects 0.000 claims description 14
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 14
- 230000002861 ventricular Effects 0.000 claims description 11
- 229940124549 vasodilator Drugs 0.000 claims description 10
- 239000003071 vasodilator agent Substances 0.000 claims description 10
- 230000006641 stabilisation Effects 0.000 claims description 9
- 238000011105 stabilization Methods 0.000 claims description 9
- 229940030606 diuretics Drugs 0.000 claims description 8
- 230000001882 diuretic effect Effects 0.000 claims description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 239000002170 aldosterone antagonist Substances 0.000 claims description 3
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 24
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 138
- 239000005541 ACE inhibitor Substances 0.000 description 53
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 53
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 49
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 46
- 108010061435 Enalapril Proteins 0.000 description 45
- 229960000873 enalapril Drugs 0.000 description 45
- 208000028659 discharge Diseases 0.000 description 41
- 101800001904 NT-proBNP Proteins 0.000 description 27
- 230000007704 transition Effects 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 15
- 230000034994 death Effects 0.000 description 15
- 231100000517 death Toxicity 0.000 description 15
- 208000001953 Hypotension Diseases 0.000 description 13
- 230000036543 hypotension Effects 0.000 description 13
- 229940100334 sacubitril / valsartan Drugs 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000002682 Hyperkalemia Diseases 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000028185 Angioedema Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000037081 physical activity Effects 0.000 description 9
- 102000003729 Neprilysin Human genes 0.000 description 8
- 108090000028 Neprilysin Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000036454 renin-angiotensin system Effects 0.000 description 6
- 241000320892 Clerodendrum phlomidis Species 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 206010061481 Renal injury Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical class C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- DOBNVUFHFMVMDB-BEFAXECRSA-N (2r,4s)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid Chemical compound C1=CC(C[C@H](C[C@@H](C)C(O)=O)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 DOBNVUFHFMVMDB-BEFAXECRSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- -1 LCZ696 Chemical compound 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 description 2
- 102000004571 Natriuretic peptide Human genes 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000000692 natriuretic peptide Substances 0.000 description 2
- 239000000712 neurohormone Substances 0.000 description 2
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 2
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 206010073257 Idiopathic angioedema Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000007889 carotid angioplasty Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 102000027424 natriuretic peptide receptors Human genes 0.000 description 1
- 108091008599 natriuretic peptide receptors Proteins 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940102035 valsartan 160 mg Drugs 0.000 description 1
- 229940051537 valsartan and sacubitril Drugs 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18190588 | 2018-08-23 | ||
| EP18190588.6 | 2018-08-23 | ||
| EP18199733 | 2018-10-10 | ||
| EP18199733.9 | 2018-10-10 | ||
| PCT/IB2019/057081 WO2020039386A1 (en) | 2018-08-23 | 2019-08-22 | New pharmaceutical use for the treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210032437A true KR20210032437A (ko) | 2021-03-24 |
Family
ID=68069829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217004177A Ceased KR20210032437A (ko) | 2018-08-23 | 2019-08-22 | 심부전의 치료를 위한 신규한 약제학적 용도 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210177803A1 (https=) |
| EP (1) | EP3840746A1 (https=) |
| JP (2) | JP2021525791A (https=) |
| KR (1) | KR20210032437A (https=) |
| CA (1) | CA3110152A1 (https=) |
| WO (1) | WO2020039386A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240173982A (ko) | 2023-06-07 | 2024-12-16 | 인제대학교 산학협력단 | 세레블론 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 심부전 진단용 바이오마커 조성물 및 치료용 약학 조성물 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| NZ533968A (en) | 2002-01-17 | 2006-10-27 | Novartis Ag | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| NZ584686A (en) | 2007-11-06 | 2013-03-28 | Novartis Ag | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate |
| AU2011293648B2 (en) | 2010-08-24 | 2015-02-12 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| AU2013304949C1 (en) | 2012-08-24 | 2020-12-24 | Novartis Ag | NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| MX363821B (es) | 2012-10-16 | 2019-04-04 | Xf Tech Inc | Conversión eficiente de alto rendimiento de monosacaridos en 5-(clorometil)-2-furaldehído. |
| ES2968541T3 (es) * | 2013-08-26 | 2024-05-10 | Novartis Ag | Tratamiento de enfermedades cardiovasculares |
| EP3038653A1 (en) * | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
| CN106414416B (zh) | 2014-09-09 | 2020-03-27 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| CN105461647B (zh) | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
| CN105503760A (zh) | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
| CN110938042B (zh) | 2014-12-08 | 2022-12-13 | 苏州晶云药物科技股份有限公司 | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法 |
| WO2016051393A2 (en) | 2014-12-26 | 2016-04-07 | Crystal Pharmatech Inc. | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof |
| WO2016125123A1 (en) | 2015-02-06 | 2016-08-11 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
| CN106032361A (zh) | 2015-03-11 | 2016-10-19 | 齐鲁制药有限公司 | Lcz-696的新晶型及其制备方法 |
| WO2016151525A1 (en) | 2015-03-26 | 2016-09-29 | Dr. Reddy’S Laboratories Limited | Crystalline form of lcz-696 |
| EP4570314A3 (en) * | 2015-05-11 | 2025-09-10 | Novartis AG | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure |
| WO2016193883A1 (en) | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| WO2016201238A1 (en) | 2015-06-12 | 2016-12-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of trisodium valsartan: sacubitril |
| CN106316973A (zh) | 2015-07-07 | 2017-01-11 | 江苏柯菲平医药股份有限公司 | 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| WO2017009784A1 (en) | 2015-07-14 | 2017-01-19 | Cadila Healthcare Limited | Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril |
| CN105037289B (zh) | 2015-07-17 | 2017-08-22 | 华东理工大学 | 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型 |
| EP3117823A1 (en) | 2015-07-17 | 2017-01-18 | Quimica Sintetica, S.A. | Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor |
| WO2017037577A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | New use |
| WO2017037596A1 (en) | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
| US10214497B2 (en) | 2015-08-28 | 2019-02-26 | Hetero Labs, LTD | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound |
| WO2017036420A1 (zh) | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| WO2017042700A1 (en) | 2015-09-07 | 2017-03-16 | Sun Pharmaceutical Industries Limited | Solid forms of valsartan and sacubitril |
| CN105669581B (zh) | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
| WO2017085573A1 (en) | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
| CN106854187B (zh) | 2015-12-08 | 2020-04-14 | 苏州晶云药物科技股份有限公司 | 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法 |
| CN105348209B (zh) | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
| CN105929031B (zh) | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
| JP7156945B2 (ja) * | 2016-02-03 | 2022-10-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
| CN107033094A (zh) | 2016-02-04 | 2017-08-11 | 南京卡文迪许生物工程技术有限公司 | 一种药物共晶的晶型及其制备方法和组合物 |
| US10703731B2 (en) | 2016-03-07 | 2020-07-07 | Msn Laboratories Private Limited | Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof |
| WO2017191619A2 (en) | 2016-05-06 | 2017-11-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of a salt of sacubitril and valsartan |
| TW201806936A (zh) | 2016-08-24 | 2018-03-01 | 中化合成生技股份有限公司 | 無定形纈沙坦/沙庫比曲三鈉鹽及其製備方法 |
| WO2018069833A1 (en) | 2016-10-10 | 2018-04-19 | Laurus Labs Limited | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof |
| WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
| RU2019115782A (ru) | 2016-10-28 | 2020-11-30 | Биокон Лимитед | Аморфный тринатрий сакубитрил вальсартан и способ его получения |
| CN106518709A (zh) | 2016-11-07 | 2017-03-22 | 济南益新医药技术有限公司 | 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法 |
| CN111592500A (zh) | 2017-01-03 | 2020-08-28 | 上海博志研新药物技术有限公司 | ARB-NEPi复合物、晶型、制备方法及应用 |
-
2019
- 2019-08-22 WO PCT/IB2019/057081 patent/WO2020039386A1/en not_active Ceased
- 2019-08-22 KR KR1020217004177A patent/KR20210032437A/ko not_active Ceased
- 2019-08-22 JP JP2021507507A patent/JP2021525791A/ja active Pending
- 2019-08-22 EP EP19778657.7A patent/EP3840746A1/en not_active Withdrawn
- 2019-08-22 CA CA3110152A patent/CA3110152A1/en active Pending
- 2019-08-22 US US17/269,310 patent/US20210177803A1/en not_active Abandoned
-
2022
- 2022-06-02 JP JP2022090079A patent/JP2022116278A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240173982A (ko) | 2023-06-07 | 2024-12-16 | 인제대학교 산학협력단 | 세레블론 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 심부전 진단용 바이오마커 조성물 및 치료용 약학 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210177803A1 (en) | 2021-06-17 |
| WO2020039386A1 (en) | 2020-02-27 |
| CA3110152A1 (en) | 2020-02-27 |
| EP3840746A1 (en) | 2021-06-30 |
| JP2022116278A (ja) | 2022-08-09 |
| JP2021525791A (ja) | 2021-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7407508B2 (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 | |
| EP3038654B1 (en) | New use | |
| US11058667B2 (en) | Sacubitril-valsartan dosage regimen for treating heart failure | |
| EP3411021B1 (en) | New use of a combination of sacubitril and valsartan | |
| US20160206597A1 (en) | New Use | |
| KR20210032437A (ko) | 심부전의 치료를 위한 신규한 약제학적 용도 | |
| HK1205930B (en) | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210210 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230504 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230710 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230504 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |